DK486588D0 - CONJUNATES OF CYTOQININES WITH IMMUNGLOBULINES - Google Patents

CONJUNATES OF CYTOQININES WITH IMMUNGLOBULINES

Info

Publication number
DK486588D0
DK486588D0 DK486588A DK486588A DK486588D0 DK 486588 D0 DK486588 D0 DK 486588D0 DK 486588 A DK486588 A DK 486588A DK 486588 A DK486588 A DK 486588A DK 486588 D0 DK486588 D0 DK 486588D0
Authority
DK
Denmark
Prior art keywords
immunglobulines
cytoqinines
conjunates
conjugates
cytokine
Prior art date
Application number
DK486588A
Other languages
Danish (da)
Other versions
DK486588A (en
Inventor
Peter Van Wussow
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of DK486588D0 publication Critical patent/DK486588D0/en
Publication of DK486588A publication Critical patent/DK486588A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07G—COMPOUNDS OF UNKNOWN CONSTITUTION
    • C07G99/00—Subject matter not provided for in other groups of this subclass
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The conjugates consist of a cytokine, for example interferon alpha, and human immunoglobulin, if required linked via an organic bridge and are used in pharmaceutical preparations for the treatment of viral infections and tumours. Compared with the free cytokine, the conjugates have a longer residence time in the plasma and tissue and thus improve the therapeutic effect.
DK486588A 1987-09-02 1988-09-01 CONJUNATES OF CYTOQININES WITH IMMUNGLOBULINES DK486588A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH335787 1987-09-02

Publications (2)

Publication Number Publication Date
DK486588D0 true DK486588D0 (en) 1988-09-01
DK486588A DK486588A (en) 1989-03-03

Family

ID=4254228

Family Applications (1)

Application Number Title Priority Date Filing Date
DK486588A DK486588A (en) 1987-09-02 1988-09-01 CONJUNATES OF CYTOQININES WITH IMMUNGLOBULINES

Country Status (15)

Country Link
EP (1) EP0305967B1 (en)
JP (1) JPS6490200A (en)
KR (1) KR890005137A (en)
AT (1) ATE88900T1 (en)
AU (1) AU627694B2 (en)
DE (1) DE3880766D1 (en)
DK (1) DK486588A (en)
ES (1) ES2054753T3 (en)
FI (1) FI884013A (en)
IL (1) IL87621A0 (en)
NO (1) NO883896L (en)
NZ (1) NZ226005A (en)
PH (1) PH26813A (en)
PT (1) PT88385B (en)
ZA (1) ZA886471B (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3818055A1 (en) * 1988-05-27 1989-11-30 Biotest Pharma Gmbh COMBINATION OF HUMAN IMMUNOGLOBULINS AND INTERLEUKIN-2 FOR THE TREATMENT OF INFECTION DISEASES
GB8820378D0 (en) * 1988-08-26 1988-09-28 Offord R E Chemical compounds
GB8820377D0 (en) * 1988-08-26 1988-09-28 Offord R E Chemical compounds
KR900005995A (en) * 1988-10-31 1990-05-07 우메모또 요시마사 Modified Interleukin-2 and Method of Making the Same
DE3839332A1 (en) * 1988-11-22 1990-05-23 Bayer Ag METHOD FOR PRODUCING SUBSTITUTED 2-CHLORINE PYRIDINES
ZA902949B (en) * 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5182107A (en) * 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5154924A (en) * 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5527527A (en) * 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US5478804A (en) * 1990-09-19 1995-12-26 The Salk Institute For Biological Studies Treatment of tumorigenic pathophysiological conditions with FGF-cytoxic conjugates
WO1992011872A1 (en) * 1991-01-03 1992-07-23 The Salk Institute For Biological Studies Mitotoxin for treatment of vascular injury
AU660168B2 (en) * 1991-02-04 1995-06-15 University Of Saskatchewan VP6 encapsulated drug delivery
PT100090A (en) * 1991-02-04 1993-07-30 Univ Saskatchewan Method for targeting and release of drugs
JP3105629B2 (en) * 1991-04-23 2000-11-06 サングスタット メディカル コーポレイション Cell activity regulating conjugates of members of specific binding pairs
EP0533006A1 (en) * 1991-09-18 1993-03-24 F.Hoffmann-La Roche & Co. Aktiengesellschaft Chimaeric interleukin 5-receptor/immunoglobulin polypeptides
US7754211B2 (en) 1992-04-10 2010-07-13 Research Development Foundation Immunotoxins directed against c-erbB-2(HER-2/neu) related surface antigens
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
ES2210514T3 (en) * 1996-04-10 2004-07-01 Sangstat Medical Corporation SPECIFIC UNION COUPLE MEMBER CYCLING CONJUGATES
IT1289608B1 (en) * 1997-02-05 1998-10-15 Angelini Ricerche Spa COMPOSITION FOR THERAPEUTIC OR DIAGNOSTIC USE ADMINISTRABLE VIA INTRANASAL, SUBLINGUAL OR VAGINAL
ES2590912T3 (en) 1997-12-08 2016-11-24 Merck Patent Gmbh Heterodimeric fusion proteins useful for targeted immunotherapy and general immune system stimulation
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
EP1200479B1 (en) 1999-08-09 2006-02-01 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
ATE336514T1 (en) 2000-02-11 2006-09-15 Merck Patent Gmbh INCREASE THE CIRCULATION HALF-LIFE OF ANTIBODIES-BASED FUSION PROTEINS
MXPA02009454A (en) 2000-03-31 2003-04-10 Purdue Research Foundation Method of treatment using ligand immunogen conjugates.
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
US7148321B2 (en) 2001-03-07 2006-12-12 Emd Lexigen Research Center Corp. Expression technology for proteins containing a hybrid isotype antibody moiety
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
AU2002308562B2 (en) 2001-05-03 2008-01-24 Merck Patent Gmbh Recombinant tumor specific antibody and use thereof
CN1555268B (en) 2001-07-17 2013-04-03 研究发展基金会 Therapeutic agents comprising pro-apoptotic proteins
JP4795640B2 (en) 2001-12-04 2011-10-19 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Immune cytokines with regulated selectivity
PT1572748E (en) 2002-12-17 2010-09-28 Merck Patent Gmbh Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
RU2369616C2 (en) 2003-12-30 2009-10-10 Мерк Патент Гмбх Fused proteins il-7
JP4987484B2 (en) 2004-01-22 2012-07-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Anticancer antibodies with reduced complement binding
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
WO2007076933A1 (en) 2005-12-30 2007-07-12 Merck Patent Gmbh Interleukin-12p40 variants with improved stability
AU2006332155B2 (en) 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
BRPI1016204A2 (en) 2009-04-22 2016-04-19 Merck Patent Gmbh antibody fusion proteins with modified fcrn binding sites
JP5879713B2 (en) * 2010-12-09 2016-03-08 ソニー株式会社 Image processing apparatus, image processing method, and program
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
CN109395064A (en) 2013-04-19 2019-03-01 赛腾制药 The derivative treatment of the cell factor of reduced vascular leak syndrome
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1564666A (en) * 1978-05-31 1980-04-10 Ng Mun Hon Heterocomplexes of interferon with immunoglobulin and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
EP0305967A2 (en) 1989-03-08
IL87621A0 (en) 1989-01-31
FI884013A (en) 1989-03-03
NO883896D0 (en) 1988-09-01
EP0305967B1 (en) 1993-05-05
DK486588A (en) 1989-03-03
EP0305967A3 (en) 1990-01-31
PT88385B (en) 1992-10-30
JPS6490200A (en) 1989-04-06
ES2054753T3 (en) 1994-08-16
FI884013A0 (en) 1988-08-31
NZ226005A (en) 1990-10-26
PH26813A (en) 1992-11-05
PT88385A (en) 1989-07-31
ATE88900T1 (en) 1993-05-15
KR890005137A (en) 1989-05-13
AU627694B2 (en) 1992-09-03
ZA886471B (en) 1989-04-26
AU2172588A (en) 1989-03-23
DE3880766D1 (en) 1993-06-09
NO883896L (en) 1989-03-03

Similar Documents

Publication Publication Date Title
DK486588A (en) CONJUNATES OF CYTOQININES WITH IMMUNGLOBULINES
DK184186D0 (en) THERAPEUTIC PREPARATION FOR TREATMENT OF VIRUSAL DISEASES
DK0911033T3 (en) Use of consensus interferon to reduce the side effects of interferon therapy in viral hepatitis
GEP19981482B (en) Use of 1,3 - Oxatiolan Nucleozides Analoges for Treatment of Hepatitis B
ATE72991T1 (en) NASAL ADMINISTRATION OF MEDICATIONS.
FI862011A0 (en) THERAPEUTIC NUCLEOSIDER.
DE68929551D1 (en) Human DNase
DK602988A (en) NUCLEOSIDE DERIVATIVES WITH ANTIVIRAL EFFECT AND PHARMACEUTICAL PREPARATIONS CONTAINING SUCH COMPOUNDS
DE59101397D1 (en) O-GLYCOSYLATED IFN ALPHA.
DE69130071D1 (en) COMPOSITION USED AS A THERAPEUTIC AGENT AGAINST CHRONIC VIRAL LIVER DISEASES
NO931413L (en) METHODS AND PREPARATIONS FOR TREATMENT OF CELL PROLIFERATION DISEASES
DE68912155D1 (en) Combination antiviral.
DK68388A (en) APPLICATION OF OXOCHINAZOLINE DERIVATIVES FOR THE PREPARATION OF MEDICINAL PRODUCTS TO TREAT HYPERURIC AEMIA
ES2037807T3 (en) MEDICINES CONTAINING IN INTERFERON COMBINATION AND 1-DEOXY-PIPERIDINES, PROCEDURE FOR THEIR MANUFACTURE AND APPLICATION.
EA199800770A1 (en) DRUGS FOR THERAPEUTIC TREATMENT OF VIRAL HEPATITIS
ES2103811T3 (en) ANTIVIRAL THERAPY.
ATE92333T1 (en) MEDICATIONS FOR THE INTRALESION TREATMENT OF SCALP-LIKE CELL CARCINOMA WITH RECOMBINANT HUMAN ALPHA INTERFERON.
DK0579765T3 (en) Method and Preparation for the Treatment of Herpes-Related Diseases
DK0427633T3 (en) Use of a polypeptide with gamma interferon activity for the preparation of pharmaceutical preparations intended for the treatment of primitive pleural cancer
ES2038578T1 (en) USE OF HUMAN G IMMUNOGLOBULINS, OR OF THESE FC FRAGMENTS, AS A PREPARATORY MEDICINE FOR THE ADMINISTRATION OF MONOCLONAL ANTIBODIES TO MEN.

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment
AHB Application shelved due to non-payment